Novavax’s Matrix-M Licensing Deal With Pfizer Could Be A Game Changer For Novavax (NVAX)

Simply Wall St.02-02

In January 2026, Novavax announced a non-exclusive, worldwide License and Option Agreement giving Pfizer access to its Matrix-M adjuvant technology for up to two infectious disease vaccine programs, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2608849288?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-02-02 01:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608849288","market":"sg","top_or_hot":-1,"title":"Novavax’s Matrix-M Licensing Deal With Pfizer Could Be A Game Changer For Novavax (NVAX)","media":"Simply Wall St.","content":"<div>\n<p>In January 2026, Novavax announced a non-exclusive, worldwide License and Option Agreement giving Pfizer access to its Matrix-M adjuvant technology for up to two infectious disease vaccine programs, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nvax/novavax/news/novavaxs-matrix-m-licensing-deal-with-pfizer-could-be-a-game\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax’s Matrix-M Licensing Deal With Pfizer Could Be A Game Changer For Novavax (NVAX)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax’s Matrix-M Licensing Deal With Pfizer Could Be A Game Changer For Novavax (NVAX)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-02 01:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nvax/novavax/news/novavaxs-matrix-m-licensing-deal-with-pfizer-could-be-a-game><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In January 2026, Novavax announced a non-exclusive, worldwide License and Option Agreement giving Pfizer access to its Matrix-M adjuvant technology for up to two infectious disease vaccine programs, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nvax/novavax/news/novavaxs-matrix-m-licensing-deal-with-pfizer-could-be-a-game\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持仓","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nvax/novavax/news/novavaxs-matrix-m-licensing-deal-with-pfizer-could-be-a-game","article_id":"2608849288","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nvax/novavax/news/novavaxs-matrix-m-licensing-deal-with-pfizer-could-be-a-game","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2608849288","pubTimestamp":1769966583,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In January 2026, Novavax announced a non-exclusive, worldwide License and Option Agreement giving Pfizer access to its Matrix-M adjuvant technology for up to two infectious disease vaccine programs, along with an upfront US$30,000,000 payment. \nThis deal highlights how Novavax is positioning Matrix-M as a platform technology that larger vaccine manufacturers may incorporate across multiple disease areas. \nNext, we’ll examine how this Matrix-M licensing agreement with Pfizer shapes Novavax’s...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4581":"高盛持仓","BK4599":"减肥药","SG9999002232.USD":"Allianz Global High Payout USD","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","NVAX":"诺瓦瓦克斯医药","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4547":"WSB热门概念","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0122379950.USD":"贝莱德世界健康科学A2","BK4592":"伊斯兰概念","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0058720904.USD":"联博国际健康护理基金A","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","BK4588":"碎股","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","BK4007":"制药","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999001176.USD":"United Global Healthcare Acc USD","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus"},"translate_title":"Novavax与辉瑞的Matrix-M许可协议可能会改变Novavax(NVAX)的游戏规则","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":1.96},"content_text":"In January 2026, Novavax announced a non-exclusive, worldwide License and Option Agreement giving Pfizer access to its Matrix-M adjuvant technology for up to two infectious disease vaccine programs, along with an upfront US$30,000,000 payment.  This deal highlights how Novavax is positioning Matrix-M as a platform technology that larger vaccine manufacturers may incorporate across multiple disease areas.  Next, we’ll examine how this Matrix-M licensing agreement with Pfizer shapes Novavax’s investment narrative amid recent share price weakness.  The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.AdvertisementWhat Is Novavax's Investment Narrative?For anyone considering Novavax, the core belief is that Matrix-M can support a sustainable, higher-margin licensing and partnership model even as traditional COVID and flu revenues face pressure and earnings are expected to decline. The new Pfizer deal, with its US$30,000,000 upfront payment and potential for a second disease field, reinforces that narrative by adding another global partner alongside Sanofi and Takeda. In the near term, though, this agreement looks more like a helpful incremental catalyst than a single, game changing event, given Novavax’s negative equity position, uneven cash generation and history of sharp share price swings. The key question now is whether a growing base of Matrix-M licenses can offset forecast revenue and earnings declines and reduce dependence on any one vaccine franchise. However, one financial risk in particular still stands out for existing shareholders.\n\nDespite retreating, Novavax's shares might still be trading above their fair value and there could be some more downside. Discover how much.Exploring Other PerspectivesNVAX 1-Year Stock Price Chart Nine Simply Wall St Community members place Novavax’s fair value between US$6.64 and US$100, reflecting very different expectations. Set that against the company’s negative equity and forecast earnings decline, and it is worth comparing several viewpoints before deciding how this story might evolve.Explore 9 other fair value estimates on Novavax - why the stock might be worth 25% less than the current price!Build Your Own Novavax NarrativeDisagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Novavax research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.Our free Novavax research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Novavax's overall financial health at a glance.Interested In Other Possibilities?These stocks are moving-our analysis flagged them today. Act fast before the price catches up:We've found 12 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.Find companies with promising cash flow potential yet trading below their fair value.Outshine the giants: these 24 early-stage AI stocks could fund your retirement.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Novavax might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608849288","isCrawlerRequest":true}